CD8A and neoplasm: In the latter case, provision of the DC growth factor Flt3L with agonistic anti-CD40 to increase the frequency of activated migratory cDC1s in LNs was sufficient to enhance TCF1+CD8+ T cell numbers and reduce tumour burden [57].